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Abstract
Background: Laparoscopy-assisted surgery, fast-track perioperative treatment are both increasingly used in
colorectal cancer treatment, for their short-time benefits of enhanced recovery and short hospital stays. However,
the benefits of the integration of the Laparoscopy-assisted surgery, fast-track perioperative treatment, and even
with the Xelox chemotherapy, are still unknown. In this study, the three treatments integration is defined as “Fast
Track Multi-Discipline Treatment Model” for colorectal cancer and this model extends the benefits to the whole
treatment process of colorectal cancer. The main purpose of the study is to explore the feasibility of “Fast Track
Multi-Discipline Treatment” model in treatment of colorectal cancer.
Methods: The trial is a prospective randomized controlled study with 2 × 2 balanced factorial design. Patients
eligible for the study will be randomized to 4 groups: (I) Laparoscopic surgery with fast track perioperative
treatment and Xelox chemotherapy; (II) Open surgery with fast track perioperative treatment and Xelox
chemotherapy; (III) Laparoscopic surgery with conventional perioperative treatment and mFolfox6 chemotherapy;
(IV) Open surgery with conventional perioperative treatment and mFolfox6 chemotherapy. The primary endpoint of
this study is the hospital stays. The secondary endpoints are the quality of life, chemotherapy related adverse
events, surgical complications and hospitalization costs. Totally, 340 patients will be enrolled with 85 patients in
each group.
Conclusions: The study initiates a new treatment model “Fast Track Multi-Discipline Treatment” for colorectal
cancer, and will provide feasibility evidence on the new model “Fast Track Multi-Discipline Treatment” for patients
with colorectal cancer.
Trial registration: ClinicalTrials.gov: NCT01080547
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Achieving a better quality of life for patients through
enhanced recovery and shorter hospital stays in colorec-
tal cancer treatment is becoming increasingly important.
Compared with open surgery, laparoscopy-assisted
surgery has been proved by consistent evidence as a safe
and effective method of colorectal cancer treatment. It
also has demonstrated the benefits in reduction of surgi-
cal injury and the improvement of short-term recovery
outcome [1-4].
Fast-track perioperative treatment, which is also
referred as Enhanced Recovery after Surgery (ERAS),
attracted much attention since Henrik Kehlet initially
raised this concept [5]. This evidence-based fast-track
perioperative treatment has been used for nearly a dec-
ade. The principle of the Fast-track treatment is to
gain faster and enhanced recovery after surgery, by
reducing unnecessary interventions which were for-
mally involved in perioperative treatment, like reducing
the fasting periods and bed rest time. Since the first
time Henrik Kehlet prompted the notion, many studies
have confirmed the advantages of the Fast-track treat-
ment, especially the advantages of accelerating the
short-term recovery, reducing the postoperative mor-
bidity, shortening the hospital stays and improving the
life quality [6-14].
Nevertheless, most recent researches into laparoscopy
and Fast-track treatment of colorectal cancer focus on
the perioperative care, which are much more related to
short-term benefits, last only 1-2 weeks perioperative. In
contrast, adjuvant chemotherapy takes up around 6
months of the whole colorectal cancer treatment, but
has been neglected in researches mentioned above at
present. So, the thoughts of combining the laparoscopy,
Fast-track perioperative treatment and adjuvant che-
motherapy naturally rise up, in the attempt to gain the
maximum benefits covering both short-term and long-
term.
Xelox and mFolfox6 chemotherapy are currently used
as two comparable effective adjuvant chemotherapies for
colorectal cancer, and Xelox chemotherapy is already
being widely used in colorectal cancer, as it has better
manageable tolerability and similar Overall Survival(OS)
[15-17] versus mFolfox6 chemotherapy.
Until now, there has been no published study
researching the effects of the combination of laparo-
scopy, Fast-track treatment and Xelox chemotherapy,
which has been focused on in this FTMDT (Fast Track
Multi-Discipline Treatment) trial. And we propose the
new model “Fast Track Multi-Discipline Treatment” for
this combination. In view of the improved rehabilitation
the three component parts bring to the colorectal cancer
treatment, we aim to find a more economical and
effective mode for colorectal cancer treatment through
this prospective randomized controlled FTMDT-trial
study.
Since it has not been established whether FTMDT is
superior to conventional treatment (open or laparo-
scopic surgery with conventional perioperative treatment
and mFolfox6 chemotherapy) in colorectal cancer treat-
ment, the following is the present study protocol.
Methods/Design
Study objectives
The general objective of this FTMDT trial is to assess,
synthesize and discuss the feasibility of “Fast Track
Multi-Discipline Treatment” model in treatment of col-
orectal cancer. It can be divided into 2 questions: 1. Is it
safe and effective to combine Xelox chemotherapy with
laparoscopy and fast-track perioperative treatment? 2. Is
laparoscopy an essential component of FTMDT and
how important a role does it play?
Study design
This FTMDT-trial is an open randomized prospective
and controlled study with 2 × 2 balanced factorial
design. Patients eligible for the criteria will be rando-
mized into four study groups (1:1:1:1) according to the
randomized figures generated by the SPSS 16.0, after the
patients signing the informed consents: (I) Laparoscopic
surgery with fast track perioperative treatment and
Xelox chemotherapy; (II) Open surgery with fast track
perioperative treatment and Xelox chemotherapy; (III)
Laparoscopic surgery with conventional perioperative
treatment and mFolfox6 chemotherapy; (IV) Open sur-
gery with conventional perioperative treatment and
mFolfox6 chemotherapy.
Chinese medical insurance system ensures that, hospi-
talization is suitable for payment and also for patients’
interest. All patients in this study will receive hospita-
lized chemotherapy in each cycle.
This trial has the independent “third-party” for devel-
oping the randomization.
Eligibility
Inclusion Criteria: patients who are 18 years and older,
with pathologically confirmed colon and upper rectal
cancer and signed informed consent prior to enrollment.
Exclusion Criteria: Tumors which can be resected by
endoscopic mucosal resection (EMR) and endoscopic
submucosal dissection (ESD), history of malignancy,
bowel obstruction or intestinal perforation, evidence of
metastasis through physical examination, chest roent-
genogram and computed tomography of liver and pelvis,
acute disease and acute attack of chronic disease, psy-
chiatric history, spinal deformity, American Society of
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Page 2 of 10Anesthesiologists (ASA) score ≥ IV, mid-low rectal can-
cer, and pregnant woman.
Adjuvant chemotherapy will be needed for III stage or
high-risk II stage pathologically established colorectal can-
cer. The performance status of the patients after surgery
will be evaluated with the Zubrod-ECOG-WHO score,
before the chemotherapy start. Patients with Zubrod-
ECOG-WHO score sustain ≥ 2 within 3 months after sur-
gery will be excluded and not have the chemotherapy.
Discontinuance criterion
The discontinuance criterion of this clinical trial as fol-
lowings: 1) the trial appears causing unexpected harm
or severe adverse events to participants, or the evidence
that the risks outweigh the benefits, with the discontinu-
ance decision of the ethics committees. 2) the enroll-
ment indicates the trial can’t be finished in the period of
4 years. 3) chemotherapy will be suspended for the
patients with the chemotherapy adverse events more
than grade 3 according to NCI-CTC AE 3.0 (National
Cancer Institute Common Terminology, Criteria for
Adverse Events 3.0). And the dose will be adjusted to
75% after adverse events reduce to grade 2 or lower.
The chemotherapy will be withdrawn once the severe
adverse events appear again.
Primary and secondary endpoint measures
The primary outcome measure of this FTMDT-trial is
the hospital stays, which is the overall hospitalization
stay during treatment including both the hospital stay
for the surgery and adjuvant chemotherapy.
We define the postoperative discharge day for the
patients in the trial when they meet all of the discharge
criteria, 1. Good pain control: NSR (Numeric Rating
Scale) ≤ 3. 2. Tolerance of solid food, no need of intra-
venous fluid infusion. 3. Independent activities of daily
living (ADL) to preoperative care level at least [18,19].
Secondary outcome measures are as follows, 1. Quality
of life according to EORTC (European Organization for
Research and Treatment) QLQ-C30 and QLQ-CR38
questionnaires, with the checkpoint frame, preoperation,
1 week post operation, 3-months post surgery and 6-
months post surgery. 2. Chemotherapy related adverse
events according to NCI CTCAE (Common Terminol-
ogy Criteria for Adverse Events) Version3.0. 3. Surgical
complications mainly include injury of the ureters,
intraoperative transfusion, infection of incision, anasto-
motic leakage and readmission. 4. Hospitalization costs
are calculated from the first day in hospital to the last
day that adjuvant chemotherapy is finished.
Participating centers
The FTMDT-trial is a multi-center study located in
China, with 3 participating centers as follows, Hangzhou
center (Department of Surgical Oncology, Second
Affiliated Hospital, Zhejiang University College of Medi-
cine), Shaoxing center (Department of Anorectum, Peo-
ple’s Hospital of Shaoxing), Wenzhou center
(Department of Anus and Large Intestine, Second
Affiliated Hospital, Wenzhou Medicine College).
Ethics
The independent medical ethics committees of the par-
ticipating hospitals have approved this FTMDT-trial
protocol, with the approval number: 2010LSY No.6. All
the procedures of this study are under the oversight of
the Chinese Ministry of Health.
Study outline
Interventions
Surgery Much experience has been accumulated since
the first laparoscopic colectomy in 2003 in Hangzhou
center, as the number of all colorectal cancer surgery
has been approximately up to 350 per year, including
about 30% open surgery and 60% laparoscopic surgery.
Shaoxing center has done approximately 400 laparo-
scopic colorectal surgeries since developed in 2004 and
Wenzhou center approximately 300 since 2005.
In this study, open and laparoscopic surgery will be per-
formed according to the principles of NCCN Clinical
Practice Guidelines in Oncology ™ Colon Cancer
V.2.2009 and there are 8 colorectal surgeon specialists, all
of whom are Attending Surgeons (Ke-Feng Ding, Xiao-
Jiang Ying, Rong Chen, Yong-Mao Song, Jian-Wei Wang,
Li-Feng Sun, Yong-Chuan Deng, Yi Shen). The former
five of them are for laparoscopy and they have performed
laparoscopic operations in colorectal cancer with a mini-
mum of 20 as suggested by the ASCRS [20,21].
Perioperative treatment Patients in groups III and IV
will receive conventional perioperative treatment, while
patients in groups I and II will receive the fast track
perioperative treatment, which will be provided by
trained doctors and nurses separately.
The essence of the fast track perioperative treatment
can be represented from 3 periods, 1. Preoperation, psy-
chological optimism and information of the fast track
treatment to patients, less time fasting, oral carbohy-
drate loaded liquids. 2. Intraoperation, combined
anesthesia consisting of epidural and general anesthesia
with the use of morphine minimized as far as possible,
minimal use and early removal of nasogastric tube,
drains and catheter, body warming as well as intrave-
nous fluid warming. 3. Post operation: pain management
without opioid, early feeding rehabilitation, restriction of
intravenous fluid infusion, early ambulation.
The comparison of fast track and conventional perio-
perative operation treatments are summarized in Table
1.
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Page 3 of 10Table 1 Checklist of fast track and conventional perioperative operation treatments
Time Fast track treatment Conventional treatment
Preadmission -Psychological optimism -No psychological optimism
(After
randomization)
-Pre-assessment for risk adjustment -Pre-assessment for risk adjustment
-Anesthesiologic information of combined
anesthesia consisting of thoracic
epidural and general anesthesia
-No Anesthesiologic information of general anesthesia
-Information of the fast track treatment and the
informed consent
-Information of the conventional treatment and the informed consent
-Guided tour of fast track wards -No tour
-Operation schedule -Operation schedule
Preoperation -Bowel preparation: semiliquid diet 1 days before
operation
-Bowel preparation: liquid diet 1-2 days before operation
- Enemas: -Enemas:
Polyethylene Glycol-Electrolyte Powder
®
(Hengkang Zhengqing™, Jiangxi
Hygecon Pharmacy CO., Ltd, Shangrao, CN) the
afternoon before surgery,2
boxes mixing with 2,000 ml warm drinking water
Polyethylene Glycol-Electrolyte Powder
® the afternoon before surgery, 2
boxes mixing with 2000 ml warm drinking water
-Fasting: last meal 2 h before operation -Fasting: last meal 10 h before operation
-Complete Enteral Nutritional Emulsion Supportan
(TPF-T)
® (Supportan™,
Sino-Swed Pharmaceutical CO. Ltd, Wuxi, CN) 600
ml or Fresubin Diabetes
(TPF-D)
® (Fresubin Diabetes™, Sino-Swed
Pharmaceutical CO. Ltd, Wuxi,
CN) 500 ml (especially for patients with diabetes
mellitus) p.o. 8 h before operation
- No oral intake in the operation day
- 10% Glucose 400 ml p.o. 2-3 h before operation - No oral intake in the operation day
- Nasogastric tube 0.5 h before operation for
Gastrointestinal decompression
- Nasogastric tube 0.5 h before operation for Gastrointestinal decompression
Intraoperation
-Anesthetic
managemen
- Placement of epidural catheter (T6-L1), depending
on the surgical resection);
test-dose (3 ml of 2% lidocaine (Hefeng™, Harvest
Pharmaceutical CO. Ltd,
Shanghai, CN)) followed by continuous infusion (10
ml of 0.5% or 0.75%
ropivacaine(Naropin™, APP Pharmaceuticals, LLC.,
Schaumburg, IL)
according to the age and size of the patient before
surgical incision
- No thoracic epidural anesthesia
- Balanced Combination with general anesthesia:
intravenous midazolam
(Liyuexi™, Nhwa Pharmaceutical Co., Ltd., Xuzhou,
CN) (0.1 mg/kg),
target-controlled infusion (TCI) of propofol
(Diprivan™,
AstraZeneca Pharmaceutical Co., Ltd.,
Shanghai, CN) (4-8 μg/ml), sufentanil (Fukang™,
Humanwell Pharmaceutical Co., Ltd., Yichang, CN)
(0.5-1 µg/kg), rocuronium
(Esmeron™, Organon Teknika B.V., Oss, NL) (0.6-0.9
mg/kg).
- Normal General anesthesia: intravenous midazolam (0.1 mg/kg), target-
controlled infusion (TCI) of propofol (4-8 μg/ml), sufentanil 0.5-1 µg/kg,
rocuronium (0.6-0.9 mg/kg).
The patients were ventilated mechanically. The patients were ventilated mechanically.
Anesthesia was maintained propofol TCI (2-4 μg/
ml), remifentanil
(0.02-0.03 μg/kg/min) and intermittent boluses of
rocuronium.
Anesthesia was maintained propofol TCI (2-4 μg/ml), remifentanil (Ruijie™,
Humanwell Pharmaceutical Co., Ltd., Yichang, CN) (0.02-0.03 μg/kg/min) and
intermittent boluses of rocuronium.
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Page 4 of 10Table 1 Checklist of fast track and conventional perioperative operation treatments (Continued)
As equally depth of anesthesia is also needed in conventional treatment
group with no thoracic epidural anesthesia, more drug dosage of general
anesthesia is used.
- Morphia as little as possible - No restriction of Morphia use
- Monitoring: (Datex Ohmeda™ S/5 Anesthesia
Monitor (Datex-Ohmeda Division,
Instrumentarium Corp., Helsinki, Finland)) consists
of electrocardiogram (ECG),
heart rate (HR), respiratory rate, arterial pressure
(BP), SpO2, end-tidal CO2
(etCO2), and bispectral index (BIS). - The target
concentration of propofol:keep
BIS between 40 and 60 to maintain adequate
hypnosis. - Perioperative
hypotension:systolic blood pressure (SBP) < 80
mmHg or a decrease
of 30% baseline value and was treated with
reduction of anesthetics,
fluid supplement, and a bolus dose of ephedrine
(Mahuangsu™, Northeast
Pharmaceutical Co., Ltd., Shenyang, CN) (10 mg, IV).
If SBP was above
160 mmHg or increase > 30%, an increase of
propofol or remifentanil infusion
was given to deepen anesthesia.
- Monitoring: the same as fast-track group
-Antibiotic
prophylaxis
- Yes, - Yes
-Surgical
management
-Laparoscopic/open surgery as randomization -Laparoscopic/open surgery as randomization
- Warming - Yes, body warming by thickening quilt as well as
intravenous fluid warming
- No body and intravenous fluid warming
- Drains - Minimal use and early removal of abdominal
drains
-Regularly use and removal of abdominal drains
- Fluid infusion - Totally ≤ 1,500 ml during operation - No restriction
Postoperation
- Pain
management
-Patient-controlled continuous epidural analgesia
with a 5 ml/h continuous
infusion of 0.15% ropivacaine and a bolus dose of
2.5 ml (locktime 15 min)
until 48 h after operation, paracetamol (Tylenol™,
Johnson & Johnson
Pharmaceutical Co., Ltd., Shanghai, CN) p.o. when
needed
-Patient-controlled intravenous analgesia with a 4 ug/h continuous infusion
of sufentanil and a bolus dose of 1.5 μg (locktime 15 min)
-Bucinperazine (QiangtongdingTM, Northeast Pharmaceutical Co., Ltd.,
Shenyang, CN) or Morphine (Mafei™, Northeast Pharmaceutical Co., Ltd.,
Shenyang, CN) intramuscular injection when patient-controlled intravenous
analgesia isn’t enough for pain control
- Diet - Chewing gum 1 piece tid p.o. -No chewing gum
- At least 10% Glucose 200 ml p.o. within 24 h after
operation
- Fasting until flatus
-Liquid diet and Enteral Nutritional Emulsion
Supportan 200 ml or
Fresubin Diabetes 300 ml (especially for patients
with diabetes mellitus)
p.o. the next day of operation
- Liquid diet after flatus
- Diet rehabilitation as early as possible (dose
increase of Enteral
Nutritional Emulsion or when needed)
- Normal diet after defecation
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Page 5 of 10Adjuvant chemotherapy In this study, adjuvant che-
motherapy for III stage or high-risk II stage pathologi-
cally established colorectal cancer includes Xelox and
mFolfox6, both of regimens which in accordance with
NCCN Clinical Practice Guidelines in Oncology ™
Colon Cancer V.2.2009.
(a) mFolfox6 (repeat every 2 weeks for 12 cycles)
Oxaliplatin (Eloxatin™, Sanofi-aventis, Hangzhou,
CN) 85 mg/m
2 IV over 2 hours, day 1
Leucovorin (Tongao™, Hengrui medicine Co., Ltd,
Lian Yuan-gang, CN) 400 mg/m
2 IV over 2 hours,
day 1
5-FU (Jinyao™, Tianjin KingYork Amino Acid Co.,
Ltd. Tianjin, CN) 400 mg/m
2 IV bolus on day 1,
then 1,200 mg/m
2/day × 2 days (total 2,400 mg/m
2
over 46-48 hours) continuous infusion
(b) Xelox, also known as CapeOX (repeat every 3
weeks for 8 cycles)
Oxaliplatin 130 mg/m
2 day 1, Capecitabine
(Xeloda™, Roche, Shanghai, CN)
850-1,000 mg/m
2 twice daily for 14 days
Patient pathway All the patients in the FTMDT trial
will go through as depicted in the flowchart (Figure 1)
Statistical analysis
Sample size calculation
Hospital stay is the primary endpoint. From the evi-
dence in the researches [13,14,22-26], we estimate the
hospital stay of laparoscopic and open surgery with
Fast-track perioperative treatment is 6 and 8 days.
Xelox chemotherapy has at most 1 hospitalization day
for each cycle followed by taking Capecitabine orally
at home, for a total of 8 cycles. Therefore, we calcu-
late the hospital stay for groups I and II at 14 and 16
Table 1 Checklist of fast track and conventional perioperative operation treatments (Continued)
- Intravenous
fluid infusion
- Stop intravenous high energy fluid infusion after
dosage of Enteral
Nutritional Emulsion Supportan ≥ 600 ml or Enteral
Nutritional
Emulsion Fresubin Diabetes ≥ 500 ml
- Intravenous high energy fluid infusion on daily basis and continuing until
adequate oral intake
- No intravenous High-energy Nutrient Fluid after
72 h post-surgery
- Restricting and avoiding excessive intravenous
fluid infusion,
keeping body weight as pre-surgery
- Energy - Keep the total energy intake (both diet and
intravenous fluid infusion)
25-30 kcal/kg/day
- Keep the total energy intake (both diet and intravenous fluid infusion) 25-
30 kcal/kg/day
- Nasogastric
tube
and urethral
catheter
-Remove nasogastric tube as soon as the end of
operation
- Remove nasogastric tube after 1st flatus postoperation
- Remove urethral catheter within 24-48 h after
operation
-Remove urethral catheter when 1st time meet: patient have the feeling of
automatic micturition and ≧200 ml after valving-on urethral catheter
- Ambulation - Forced ambulation within 24 h post-surgery, no
time restriction
- No ambulation scheme
- Ambulation time ≥ 1 h per day, and increasing
day by day
- Patients walking to weight themselves every day
Adjuvant
chemotherapy - Xelox - mFolfox6
- repeat every 3 weeks for 8 cycles - repeat every 2 weeks for 12 cycles
- Regimen - Regimen
Oxaliplatin 130 mg/m2 day 1, Capecitabine
(Xeloda™) 850-1,000
mg/m2 twice daily for 14 days -
Oxaliplatin (Eloxatin
TM) 85 mg/m2 IV over 2 hours, day .1 Leucovorin
(Tongao™) 400 mg/m2 IV over 2 hours, day 1. 5-FU (Jinyao™) 400 mg/m2
IV bolus on day 1, then 1,200 mg/m2/day × 2 days (total 2,400 mg/m2 over
46-48 hours) continuous infusion
- No peripherally inserted central catheter (PICC) - Peripherally inserted central catheter and care of PICC in outpatient clinic
every week
- Hospitalization no more than 24 h each cycle - Hospitalization for 3 days each cycle
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Page 6 of 10days. According to our previous research [27], the
hospital stay of laparoscopic and open surgery with
conventional perioperative treatment is 12 and 14
days. mFolfox6 chemotherapy requires at least 3 hos-
pitalization days for each cycle, totally 12 cycles. So,
we calculate the hospital stay of III and IV group is 48
and 50 days.
With the standard deviation of 6 days of mean hospi-
talization days, a total sample size of 218 would have a
power of > 0.85 to detect a minimum reduction of 2
days in hospital stay among the 4 groups, using a 5%
significance level. The III stage or high-risk II stage
account for 64% of the total colorectal cancer patients
[28], and these patients need the adjuvant chemotherapy
according to the NCCN Clinical Practice Guidelines in
Oncology-Colon Cancer Guideline 2009 (Version
2.2009) [29]. For this trial we will enroll 340 patients
and have 85 patients in each group.
Economic evaluation
As one of the secondary outcomes, we would analyze
the balance between the reduction of hospitalization
days and the hospitalization cost, and evaluate whether
or not FTMDT is a more economical colorectal disease
treatment model.
Outpatients with Colorectal Cancer
Eligibility Exclusion
Inclusion
 Randomization  by random number 
generated by the SPSS 16.0
Informed Consent
Surgery
Fast Track
 Treatment
Conventional
Treatment Perioperative
Treatment
 Meet the discharge criteria 
Discharge
     XELOX (CapeOX):
     Repeat every 3 weeks, for 8 cycles
Chemotherapy      mFOLFOX6:
     Repeat every 2 weeks, for 12 cycles
I Groups II III IV
I and II groups III and IV groups
       Primary Endpoint:  Hospitalization day
       Secondary Endpoints:  1. Quality of life;       2. Chemotherapy related adverse event;
                                            3. Surgical complications;       4. Hospitalization costs
Endpoints
Laparoscopic 
surgery Open Surgery Laparoscopic 
surgery Open Surgery
Stage III and stage II with high-risks
Figure 1 The FTMDT trial flowchart.
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Page 7 of 10Data collection and monitoring
All the data will be collected by assigned persons: the
information of surgery and perioperative treatment will
be collected during hospitalization, and the information
of chemotherapy will be followed up.
A professional research associate develops regular
contact between the study centers and monitors the
information for each patient.
Discussion
As we know, the surgery, perioperative treatment and
chemotherapy for colorectal cancer stretches roughly to
half a year at present, which means a long hospital stay
for the patients and high medical resource costs.
As a result, two demand-oriented feasible methods
have been brought into the colorectal cancer treatment,
laparoscopic surgery and fast-track perioperative
treatment.
For laparoscopic surgery, the COST Study Group trial
has proved the advantages of laparoscopy for colon can-
cer, especially in faster perioperative recovery and
shorter hospital stays, with the similar recurrence and
overall survival rates to the open-colectomy group [1].
The UK MRC CLASICC Trial also demonstrated that
laparoscopy-colectomy is as effective as open surgery in
terms of oncological outcomes [30]. For Fast-track peri-
operative treatment, the LAFA Study Group and ERAS
Group presented a systematic evidence-based consensus
review, proving that Fast Track treatment appears to be
safe and can shorten the hospital stay after elective col-
orectal surgery [9]. All the studies above provided the
feasibility and safety of both laparoscopic surgery and
fast-track perioperative treatment.
However, it is important to point out that, the
enhanced recovery mentioned in current study about
laparoscopy and Fast-track, is confined to the short-
term postoperative recovery, which only lasts 1-2 weeks
perioperatively. The previous study showed that quality
of life benefits due to minimally invasive laparoscopic
surgery were evident only in the immediate postopera-
tive period [31]. As a result, the long-term benefit relies
on the innovative treatment model covering not only
surgery but also adjuvant chemotherapy. It’s significant
and interesting to investigate whether it will be possible
to cover the enhanced recovery over the whole colorec-
tal cancer treatment and how it works. Consequently,
combining the long-term benefit chemotherapy treat-
ment is taken into consideration.
The NO16968/XELOXA study discovered that the
Xelox chemotherapy used as an adjuvant chemotherapy
for colorectal cancer become possible now, as it has a
manageable tolerability profile in adjuvant setting [17].
In each cycle of Xelox chemotherapy, there is only 1
day hospital stay for intravenous Oxaliplatin and the
Capecitabine intake from 1st to14th day can be done in
home. And in mFolfox6 chemotherapy, each cycle needs
3 days hospital stay in China. Consequently, it can be
seen clearly that the superiority of Xelox for shorter
hospital stay with the similar Overall Survival (OS) to
mFolfox6.
On this consideration, before this trial, KF Ding has
been conducting an open nonrandomized prospective
study comparing laparoscopic surgery with Xelox che-
motherapy and open surgery with mFolfox6 chemother-
apy for resectable colorectal cancer, and the interim
analysis has proved that the former provides faster post-
operative recovery and potentially sustained better qual-
ity of life throughout treatment [32].
In the view of the separate superiority of the laparo-
scopy, Fast-track perioperative treatment and Xelox che-
motherapy, and the possibility of the integration of
these three essential treatments in colorectal cancer, the
new notion “Fast Track Multi-Discipline Treatment”
(FTMDT) for the integration of these three treatments
is promoted in this FTMDT trial. And this FTMDT
model is supposed to substantially reduce the length of
hospital stays with equal safety and effectiveness, gain
the better long-term recovery outcomes, and give
patients a better quality of life.
The 2 × 2 balanced factorial design for this rando-
mized prospective controlled FTMDT study tries to
answer 2 corresponding questions. The I and II groups
versus the III and IV groups is designed to answer the
research question “Is Fast-track multidiscipline treat-
ment model safe and effective, compared to conven-
tional treatment?”, while the I group versus II group
aims to answer “Is laparoscopy an essential component
of FTMDT-trial and how important role does it play?”
It’s necessary to mention that, the second question
about the necessity of laparoscopy use is closely related
to the treatment cost. On one hand, the use of laparo-
scopy itself will increase the operation cost, compared
to the open operation; on the other hand, the shorter
hospital stay if the laparoscopy could bring, will conver-
sely bring the reduction of the treatment cost. It is still
unknown whether laparoscopic surgery has a beneficial
effect on Fast-track perioperative treatment, although
the most recent studies have proved that the laparo-
scopic surgery with Fast-track treatment also has shorter
hospital stay and enhanced recovery [22-26]. However,
research has found that there is no further benefit for
the laparoscopy, compared with open surgery groups,
and even with the two groups both using Fast-track
perioperative treatment [33-35]. And some trials are still
undergoing now to try to answer the question, like
LAFA-trial which is now being conducted in Nether-
lands [36]. Consequently, it can be assumed that, if the
laparoscopy did not play the essential role in enhanced
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Page 8 of 10recovery and reduced hospitalization, the use of laparo-
scopy in the Fast-track perioperative treatment could be
considered again and the extra cost by laparoscopic
appliance using may save.
The LAFA-trial which is now being conducted in the
Netherlands has combined laparoscopy with fast track
perioperative care, which will provide the merits of fast
track perioperative care and laparoscopic colectomy
[36]. Additionally, in this FTMDT trial the perioperative
treatment of enhanced recovery for colorectal cancer
treatment has the similar principle to the ERAS Group
or LAFA Group [12,36], but involves the chemotherapy
into study and also has a different definition for Fast
track treatment. In this FTMDT trial, the notion of Fast
Track treatment, is not only limited to the perioperative
care but extended to the entirety of the colorectal can-
cer treatment, involving surgery, the perioperative treat-
ment and the adjuvant chemotherapy. Correspondingly,
the short-term superiority of the laparoscopic surgery
and fast-track perioperative treatment, the long-term
superiority of Xelox chemotherapy, may integrate
together. Thereby, this FTMDT model covers the whole
colorectal cancer treatment periods, makes it possible to
achieve the whole process enhanced recovery and bring
the economic benefits synonymously.
Concretely, at least 3 aspects of the advantage for the
“Fast Track Multi-Discipline Treatment” Model are
expected: 1. The whole process enhanced recovery: The
FTMDT model itself covers the entire treatment pro-
cesses for colorectal cancer. The patients who receive
the laparoscopic surgery, fast-track perioperative treat-
ment have enhanced short-term recovery, and can enter
the chemotherapy earlier with good physical condition,
and can also further earn the life quality benefits from
the Xelox chemotherapy. 2. The economic benefits: The
FTMDT model can substantially reduce the hospitaliza-
tion stay because of enhanced recovery and convenient
Xelox chemotherapy bring. The medical resources can
be saved and the medical cost for colorectal cancer may
decline as the result of decreased hospitalization stay.
Moreover, Winterhalder reported Xelox is cost saving
versus Folfox4, presenting the economic benefits of
Xelox chemotherapy [37]. 3. The strengthened confi-
dence of patients: The patients in the Fast Track Multi-
Discipline Treatment arm earn the enhanced recovery,
higher life quality, shorter hospital stay and the lighter
economic burden, making patients the firmer faith
against cancer and confidence for the further life.
In summary, this FTMDT trial gives insights into the
potential merits and feasibility of the “Fast Track Multi-
Discipline Treatment” model. A new guideline of whole
process enhanced recovery treatment for colorectal can-
cer will be established according to the FTMDT model.
This model will create another effective treatment
pathway, bring economic benefits, and make the color-
ectal cancer treatment cost-saving and efficacy-gaining.
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